Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evalua...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jie Zhang PhD, Di Wu PhD, Ziran Zhang PhD, Jieran Long PhD, Guangming Tian PhD, Yang Wang PhD, Xiangjuan Ma PhD, Xiaoling Chen PhD, Jindi Han PhD, Weiheng Hu PhD, Ling Dai PhD, Jun Nie PhD, Jian Fang PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/31934071c47149bf87053edf3807d5a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31934071c47149bf87053edf3807d5a3
record_format	dspace
spelling	oai:doaj.org-article:31934071c47149bf87053edf3807d5a32021-12-02T01:04:19ZPembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study1533-033810.1177/15330338211039676https://doaj.org/article/31934071c47149bf87053edf3807d5a32021-11-01T00:00:00Zhttps://doi.org/10.1177/15330338211039676https://doaj.org/toc/1533-0338Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evaluate the response and complications of patients with advanced NSCLC treated with pembrolizumab or bevacizumab plus chemotherapy. Methods: This study was a retrospective cohort study of patients with advanced nonsquamous NSCLC who received cisplatin with pemetrexed combined with pembrolizumab (A group) or bevacizumab (B group) from 07/02/2018 to 07/03/2021 at Peking University Cancer Hospital. Progression-free survival (PFS) was the primary outcome. The secondary outcomes included overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and adverse events (AEs). Results: This study included 66 patients, 34 in A group and 32 in B group. There were no differences in median PFS (7.6 vs 9.9 months, P = .601). There were no differences in median OS (23.1 vs 24.2 months, P = .782). There were no differences in ORR (57.6 % vs 41.9 % , P = .211) and DCR (93.9 % vs 100.0 % , P = .164) between 2 groups. The occurrence of AEs was similar. No new safety signals were observed. Grade 3 to 4 treatment-related AEs occurred in 17 (50.0 % ) patients of A group and in 12 (37.5 % ) of B group ( P > .05). Conclusion: The addition of pembrolizumab or bevacizumab to pemetrexed plus cisplatin was well tolerated and resulted in a clinically meaningful treatment benefit in advanced nonsquamous NSCLC. When pembrolizumab is not suitable, bevacizumab plus chemotherapy may be an option.Jie Zhang PhDDi Wu PhDZiran Zhang PhDJieran Long PhDGuangming Tian PhDYang Wang PhDXiangjuan Ma PhDXiaoling Chen PhDJindi Han PhDWeiheng Hu PhDLing Dai PhDJun Nie PhDJian Fang PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jie Zhang PhD Di Wu PhD Ziran Zhang PhD Jieran Long PhD Guangming Tian PhD Yang Wang PhD Xiangjuan Ma PhD Xiaoling Chen PhD Jindi Han PhD Weiheng Hu PhD Ling Dai PhD Jun Nie PhD Jian Fang PhD Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
description	Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in randomized controlled studies. The study aimed to evaluate the response and complications of patients with advanced NSCLC treated with pembrolizumab or bevacizumab plus chemotherapy. Methods: This study was a retrospective cohort study of patients with advanced nonsquamous NSCLC who received cisplatin with pemetrexed combined with pembrolizumab (A group) or bevacizumab (B group) from 07/02/2018 to 07/03/2021 at Peking University Cancer Hospital. Progression-free survival (PFS) was the primary outcome. The secondary outcomes included overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and adverse events (AEs). Results: This study included 66 patients, 34 in A group and 32 in B group. There were no differences in median PFS (7.6 vs 9.9 months, P = .601). There were no differences in median OS (23.1 vs 24.2 months, P = .782). There were no differences in ORR (57.6 % vs 41.9 % , P = .211) and DCR (93.9 % vs 100.0 % , P = .164) between 2 groups. The occurrence of AEs was similar. No new safety signals were observed. Grade 3 to 4 treatment-related AEs occurred in 17 (50.0 % ) patients of A group and in 12 (37.5 % ) of B group ( P > .05). Conclusion: The addition of pembrolizumab or bevacizumab to pemetrexed plus cisplatin was well tolerated and resulted in a clinically meaningful treatment benefit in advanced nonsquamous NSCLC. When pembrolizumab is not suitable, bevacizumab plus chemotherapy may be an option.
format	article
author	Jie Zhang PhD Di Wu PhD Ziran Zhang PhD Jieran Long PhD Guangming Tian PhD Yang Wang PhD Xiangjuan Ma PhD Xiaoling Chen PhD Jindi Han PhD Weiheng Hu PhD Ling Dai PhD Jun Nie PhD Jian Fang PhD
author_facet	Jie Zhang PhD Di Wu PhD Ziran Zhang PhD Jieran Long PhD Guangming Tian PhD Yang Wang PhD Xiangjuan Ma PhD Xiaoling Chen PhD Jindi Han PhD Weiheng Hu PhD Ling Dai PhD Jun Nie PhD Jian Fang PhD
author_sort	Jie Zhang PhD
title	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
title_short	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
title_full	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
title_fullStr	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
title_full_unstemmed	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
title_sort	pembrolizumab or bevacizumab plus chemotherapy as first-line treatment of advanced nonsquamous nonsmall cell lung cancer: a retrospective cohort study
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/31934071c47149bf87053edf3807d5a3
work_keys_str_mv	AT jiezhangphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT diwuphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT ziranzhangphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT jieranlongphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT guangmingtianphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT yangwangphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT xiangjuanmaphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT xiaolingchenphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT jindihanphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT weihenghuphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT lingdaiphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT junniephd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy AT jianfangphd pembrolizumaborbevacizumabpluschemotherapyasfirstlinetreatmentofadvancednonsquamousnonsmallcelllungcanceraretrospectivecohortstudy
_version_	1718403307608735744

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study

Ejemplares similares